124 related articles for article (PubMed ID: 12591991)
1. Re: Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer.
Pisal N; Sindos M; Singer A
J Natl Cancer Inst; 2003 Feb; 95(4):331; author reply 331-2. PubMed ID: 12591991
[No Abstract] [Full Text] [Related]
2. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer.
Chang HW; Lee SM; Goodman SN; Singer G; Cho SK; Sokoll LJ; Montz FJ; Roden R; Zhang Z; Chan DW; Kurman RJ; Shih IeM
J Natl Cancer Inst; 2002 Nov; 94(22):1697-703. PubMed ID: 12441325
[TBL] [Abstract][Full Text] [Related]
3. Elevated ovarian cancer marker (CA-125) in cirrhotic patients with intractable ascites.
Zamir D; Jarchovsky J; Singer C; Weiner P
J Clin Gastroenterol; 1998 Sep; 27(2):154-5. PubMed ID: 9754780
[No Abstract] [Full Text] [Related]
4. [Diagnostic value of the morphological ultrasound score system and the serum concentration of CA 125 in the diagnosis of malignant ovarian cancer].
Brazert J; Pietryga M; Szabłoński W; Persona-Sliwińska A; Biczysko R
Ginekol Pol; 2003 Dec; 74(12):1542-8. PubMed ID: 15029747
[TBL] [Abstract][Full Text] [Related]
5. [Usefulness of clinical evaluation for the level of CA-125 antigen and ultrasonographic color Doppler examination in diagnosis of ovarian tumor].
Czekierdowski A; Zrubek H; Sikorski M; Wiktor H; Józefczak M; Stachowicz N
Ginekol Pol; 1996 Nov; 67(11):552-6. PubMed ID: 9289441
[TBL] [Abstract][Full Text] [Related]
6. The clinical value of tumour markers in the management of ovarian cancer.
Rustin GJ
Ann Clin Biochem; 1996 Jul; 33 ( Pt 4)():284-9. PubMed ID: 8836386
[No Abstract] [Full Text] [Related]
7. Limitations to the use of the CA-125 antigen level in ovarian cancer.
Markman M
Curr Oncol Rep; 2003 Jul; 5(4):263-4. PubMed ID: 12781066
[No Abstract] [Full Text] [Related]
8. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup.
Vergote I; Rustin GJ; Eisenhauer EA; Kristensen GB; Pujade-Lauraine E; Parmar MK; Friedlander M; Jakobsen A; Vermorken JB
J Natl Cancer Inst; 2000 Sep; 92(18):1534-5. PubMed ID: 10995813
[No Abstract] [Full Text] [Related]
9. Evaluation of HE4 and TTR for diagnosis of ovarian cancer: Comparison with CA-125.
Zheng X; Chen S; Li L; Liu X; Liu X; Dai S; Zhang P; Lu H; Lin Z; Yu Y; Li G
J Gynecol Obstet Hum Reprod; 2018 Jun; 47(6):227-230. PubMed ID: 29609043
[TBL] [Abstract][Full Text] [Related]
10. Tumour markers in ovarian cancer.
Kehoe S; Selman T
Hosp Med; 2001 Aug; 62(8):452-3. PubMed ID: 11530581
[No Abstract] [Full Text] [Related]
11. How to interpret serum CA 125 levels in patients with serosal involvement? A clinical dilemma.
Sevinc A; Camci C; Turk HM; Buyukberber S
Oncology; 2003; 65(1):1-6. PubMed ID: 12837976
[TBL] [Abstract][Full Text] [Related]
12. [Challenge of evidence-based medicine: sense and non-sense of diagnostic tests in gynecology].
Sehouli J; Stengel D; Hindenburg J; Camara O; Porzsolt F; Lichtenegger W;
Zentralbl Gynakol; 2001 Mar; 123(3):127-31. PubMed ID: 11340951
[TBL] [Abstract][Full Text] [Related]
13. [Expression of CA-125 in ovarian cancer].
Mircea R; Frîncu DL; Dumitrache F
Rev Med Chir Soc Med Nat Iasi; 2009; 113(4):1191-4. PubMed ID: 20191897
[TBL] [Abstract][Full Text] [Related]
14. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology.
Mok SC; Chao J; Skates S; Wong K; Yiu GK; Muto MG; Berkowitz RS; Cramer DW
J Natl Cancer Inst; 2001 Oct; 93(19):1458-64. PubMed ID: 11584061
[TBL] [Abstract][Full Text] [Related]
15. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions.
Skates SJ; Horick N; Yu Y; Xu FJ; Berchuck A; Havrilesky LJ; de Bruijn HW; van der Zee AG; Woolas RP; Jacobs IJ; Zhang Z; Bast RC
J Clin Oncol; 2004 Oct; 22(20):4059-66. PubMed ID: 15381683
[TBL] [Abstract][Full Text] [Related]
16. CA125 and HE4: Measurement Tools for Ovarian Cancer.
Zhao T; Hu W
Gynecol Obstet Invest; 2016; 81(5):430-5. PubMed ID: 27160726
[TBL] [Abstract][Full Text] [Related]
17. Is CA 125 actually a tumor marker for ovarian cancer?
Collazos J
Acta Oncol; 1995; 34(2):268. PubMed ID: 7718270
[No Abstract] [Full Text] [Related]
18. [Predictive value of CA 125 in detection of ovarian cancer in pre- and postmenopausal patients].
Grzybowski W; Beta J; Fritz A; Durczyński A; Bidziński M; Grabiec M; Jakimiuk AJ
Ginekol Pol; 2010 Jul; 81(7):511-5. PubMed ID: 20825052
[TBL] [Abstract][Full Text] [Related]
19. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).
Rustin GJ; Quinn M; Thigpen T; du Bois A; Pujade-Lauraine E; Jakobsen A; Eisenhauer E; Sagae S; Greven K; Vergote I; Cervantes A; Vermorken J
J Natl Cancer Inst; 2004 Mar; 96(6):487-8. PubMed ID: 15026475
[No Abstract] [Full Text] [Related]
20. A caveat for OV-Monitor (CA 125 antigen) measurement: something is improving, something is not.
Dorizzi RM; Meneghelli S; Rocca M; Ferrari A
Clin Chem Lab Med; 2006; 44(11):1386-7; author reply 1388. PubMed ID: 17087656
[No Abstract] [Full Text] [Related]
[Next] [New Search]